Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

• ClinicalTrials.gov Identifier: NCT00571298
• Recruitment Status: Completed
• First Posted: December 11, 2007
• Last Update Posted: January 23, 2017
• Sponsor: Brigham and Women's Hospital
• Collaborator: Dana-Farber Cancer Institute
• Information provided by (Responsible Party): Raphael Bueno, MD, Dana-Farber Cancer Institute

Study Description

Brief Summary:

RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is currently used safely as in intra-operative treatment for malignant pleural mesothelioma. This study is aimed to determine if the addition of gemcitabine as a second intracavitary chemotherapy can be accomplished safely.

PURPOSE: This is a Phase I trial to study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.

Condition or disease	Intervention/treatment	Phase
Malignant Pleural Mesothelioma	Procedure: Extrapleural pneumonectomy (EPP); Drug: Cisplatin; Drug: gemcitabine; Drug: amifostine; Drug: sodium thiosulfate; Procedure: Pleurectomy/Decortication	Phase 1

Detailed Description:

• This is a dose escalation study of gemcitabine with a fixed dose of cisplatin
• Patients will undergo cytoreductive surgery, which entails the removal of the inner and outer lining of the lung (pleurectomy/decortication) with or without the lung itself (extrapleural pneumonectomy), including the lining overlying the pericardium and diaphragm. Resection of the pericardium and diaphragm are occasionally necessary to remove all visable tumor. This surgery is part of standard care for malignant pleural mesothelioma.
• After surgery, a one hour lavage with heated cisplatin and or gemcitabine will be administered to the hemithorax (and abdominal regions if the diaphragm is no longer present).
• Patients will remain hospitalized until they have recovered from surgery (usually 7-14 days).
• Patients will return to the hospital during the first month after their surgery to be evaluated by the medical staff.
• Dose escalation: 1) Three patients will be treated at the first dose level of gemcitabine. Labs will be monitored on a weekly basis, including a CBC, Chem-7, and LFT's. In the absence of developing dose-limiting toxicity (DLT) among the first 3 patients treated, dosages can be escalated. DLT will be defined as any grade 3 or higher renal toxicity, thrombocytopenia or other grade 3 toxicity not related to surgery 2) If none of these 3 patients have any toxicity, we will proceed to the next level of gemcitabine. 3) If DLT occurs in 1 of 3 patients at a given dose level, then 3 additional patients are added at that dose (for a total of 6 at this level)If no DLT occurs, we will proceed to the next level of gemcitabine. If DLT occurs in another patient, this dose is considered the maximum tolerated dose (MTD). 4) At any dose, 3 cases of DLT lead to discontinuation of recruitment at that dose and enrollment of 3 additional patients at a lower dose.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 141 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma
• Study Start Date: November 2007
• Actual Primary Completion Date: November 2011
• Actual Study Completion Date: June 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Extrapleural pneumonectomy (EPP); This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate	Procedure: Extrapleural pneumonectomy (EPP); Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm); Drug: Cisplatin; Given after the tumor is removed as a bath (perfusion) for one-hour; Other Name: Platinol; Drug: gemcitabine; Given after the tumor is removed as a bath (perfusion) for one-hour; Other Name: Gemzar; Drug: amifostine; Given intravenously before perfusion chemotherapy and then 2 hours after the first dose; Drug: sodium thiosulfate; Given intravenously immediately at the end of perfusion chemotherapy
Experimental: Pleurectomy/Decortication (P/DC); This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate	Drug: Cisplatin; Given after the tumor is removed as a bath (perfusion) for one-hour; Other Name: Platinol; Drug: gemcitabine; Given after the tumor is removed as a bath (perfusion) for one-hour; Other Name: Gemzar; Drug: amifostine; Given intravenously before perfusion chemotherapy and then 2 hours after the first dose; Drug: sodium thiosulfate; Given intravenously immediately at the end of perfusion chemotherapy; Procedure: Pleurectomy/Decortication; Resection of the lining of the lung (pleura), while the lung remains intact.
Experimental: Tumor Debulking (TD); This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate	Drug: Cisplatin; Given after the tumor is removed as a bath (perfusion) for one-hour; Other Name: Platinol; Drug: gemcitabine; Given after the tumor is removed as a bath (perfusion) for one-hour; Other Name: Gemzar; Drug: amifostine; Given intravenously before perfusion chemotherapy and then 2 hours after the first dose; Drug: sodium thiosulfate; Given intravenously immediately at the end of perfusion chemotherapy

Outcome Measures

Primary Outcome Measures :

1. To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma. [ Time Frame: 2 years ]

Secondary Outcome Measures :

1. To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity. [ Time Frame: 2 years ]
2. To study the pharmacokinetics of gemcitabine and cisplatin combination administered in this way. [ Time Frame: 2 years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically-proven diagnosis of stages I to III malignant mesothelioma of the pleura and negative mediastinal N2 lymph nodes (Malignancy is confined to the affected hemithorax)
• Adequate organ function including the following: adequate cardiac function, pulmonary function, renal and hepatic function and bone marrow reserve
• Adequate overall physical activity
• Surgical candidate for cytoreductive surgery

Exclusion Criteria:

• Extended disease outside the ipsilateral hemithorax as proven histologically, radiologically and/or intraoperatively
• Have received chemotherapy and or radiation therapy within the last 3 years at the time of study entry
• Serious concomitant systemic disorders
• Second active primary malignancy (to exclude non- melanoma skin cancer)
• Pregnancy at the time of the operation
• Psychiatric or addictive disorder which would preclude obtaining informed consent

Contacts and Locations

Locations

United States, Massachusetts

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Investigators

• Principal Investigator: Raphael Bueno, MD; Brigham and Women's Hospital

More Information

Additional Information:

Brigham and Women's Hospital, Mesothelioma and International Mesothelioma Program 

• Responsible Party: Raphael Bueno, MD, Principal Investigator, Dana-Farber Cancer Institute
• ClinicalTrials.gov Identifier: NCT00571298
• Other Study ID Numbers: 07-091
• First Posted: December 11, 2007
• Last Update Posted: January 23, 2017
• Last Verified: January 2017

Keywords provided by Raphael Bueno, MD, Dana-Farber Cancer Institute:

Extrapleural pneumonectomy; Pleurectomy Decortication; Mesothelioma; cisplatin; gemcitabine; amifostine; sodium thiosulfate

Additional relevant MeSH terms:

Mesothelioma; Mesothelioma, Malignant; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Mesothelial; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Pleural Neoplasms; Lung Diseases; Respiratory Tract Diseases; Sodium thiosulfate; Gemcitabine; Amifostine; Antineoplastic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Radiation-Protective Agents; Protective Agents; Physiological Effects of Drugs; Antidotes; Antioxidants; Antitubercular Agents; Anti-Bacterial Agents; Anti-Infective Agents; Chelating Agents